Aragen Protein Science Solutions: Industry Leading Upstream And Downstream Capabilities

Biopharmaceutical production begins with the upstream process, where engineered mammalian or microbial cells produce a specific biologic in small quantities, followed by large-scale production in bioreactors. Afterward, the biopharmaceutical is purified by removing host cell proteins, debris, and waste. In mammalian cultures, the protein is secreted into the media, while in microbial production, the protein accumulates within cells and requires cell disruption and purification. Insoluble proteins, known as inclusion bodies, are refolded to achieve their native conformation.

Aragen Life Sciences, with over two decades of experience, offers comprehensive upstream and downstream solutions for biopharmaceutical production. Our expert team works in state-of-the-art facilities to provide custom solutions for expressing biologics, process development, high-throughput analytics, and purification. We ensure that all biopharmaceuticals meet regulatory standards for safety, purity, potency, and immunogenicity while remaining scalable, compliant, and cost-effective for large-scale cGMP manufacturing.